2. Academic Validation
  3. Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents

Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents

  • J Med Chem. 2006 Jul 13;49(14):4055-8. doi: 10.1021/jm0605029.
Jie-Fei Cheng 1,  Yujin Huang,  Richard Penuliar,  Masahiro Nishimoto,  Larry Liu,  Thomas Arrhenius,  Guang Yang,  Eoin O'leary,  Miguel Barbosa,  Rick Barr,  Jason R B Dyck,  Gary D Lopaschuk,  Alex M Nadzan
Affiliations

Affiliation

  • 1 Department of Chemistry, Chugai Pharma USA, LLC., 6275 Nancy Ridge Drive, San Diego, California 92121, USA. jcheng@trlusa.com
PMID: 16821767 DOI: 10.1021/jm0605029
Abstract

Discovery of 5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-4,5-dihydroisoxazole-3-carboxamides as a new class of malonyl-coenzyme A decarboxylase (MCD) inhibitors is described. tert-Butyl 3-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-4,5-dihydroisoxazole-3-carboxamido)butanoate (5, CBM-301940) exhibited excellent potency and in vivo PK/ADME properties. It is the most powerful stimulant of glucose oxidation reported to date in isolated working rat hearts. Compound 5 improved the cardiac efficiency and function in a rat heart global ischemia/reperfusion model, suggesting MCD inhibitors may be useful for the treatment of ischemic heart diseases.

Figures
Products